November 8-10, 2021 | Virtual Conference

Register Now en English


Robert Dorsam, PhD

Director, Division of Pharm Tox Review, Office of Safety & Clinical Evaluation, OGD, CDER

Robert T. Dorsam earned his Ph.D. in Pharmacology from Temple University School of Medicine and conducted post-doctoral research in the laboratory of Silvio Gutkind, Ph.D. at the National Institutes of Health.

Bob then joined FDA where he was a Pharmacology/Toxicology reviewer in FDA’s Office of New Drugs in the areas of oncology and nonprescription products. Bob later joined the Office of Generic Drugs (OGD) as a team leader and then became Associate Director of Pharmacology/Toxicology in OGD’s Division of Clinical Review. He has been a member of CDER’s Nitrosamines Task Force since its inception and is involved safety assessments for nitrosamines in generic drug products.

Get Started & Register

Whether you are an AAM member, general attendee, or exhibitor, come meet the leaders and decision-makers who are determining the future of generics and biosimilars.

Register Now

Skip to content